ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation

被引:24
作者
Stussi, Georg
Halter, Joerg
Schanz, Urs
Seebach, Joerg D.
机构
[1] Univ Zurich Hosp, Lab Transplantat Immunol, Dept Internal Med, CH-8091 Zurich, Switzerland
[2] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland
[3] Univ Zurich Hosp, Clin Hematol, Dept Internal Med, CH-8091 Zurich, Switzerland
关键词
D O I
10.1016/j.transci.2006.05.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In contrast to solid organ transplantation (SOT), ABO-histo blood group incompatibility is of minor importance for hematopoietic stem cell transplantation (HSCT). Patients receiving ABO-incompatible HSCT are at an increased risk for immune-mediated hematological complications including immediate and delayed hemolysis, late red blood cell engraftment and pure red cell aplasia, but seem not to have a worse overall survival or increased transplant-related mortality. This review gives an overview of the immunological mechanisms leading to complications associated with ABO-incompatible HSCT and describes approaches to prevent them. The current organ shortage in SOT stimulates the exploration of new strategies to expand the donor pool including ABO-incompatible SOT and xenotransplantation. Here, we discuss the hypothesis that ABO-incompatible transplantation may be viewed as a human in vivo model for the humoral immune mechanisms of antigen-mismatched transplantation. ABO-incompatible HSCT and SOT provide excellent possibilities to analyze graft accommodation and transplantation tolerance. Understanding the underlying mechanisms of graft survival in ABO-incompatible transplantation may facilitate new strategies to overcome the immunological barriers in SOT and xenotransplantation. (c) 2006 Published by Elsevier Ltd.
引用
收藏
页码:59 / 69
页数:11
相关论文
共 106 条
[91]   Passenger B-lymphocyte-induced severe hemolytic disease after allogeneic peripheral blood stem cell transplantation [J].
Toren, A ;
Dacosta, Y ;
Manny, N ;
Varadi, G ;
Or, R ;
Nagler, A .
BLOOD, 1996, 87 (02) :843-844
[92]   Processing of major ABO-incompatible bone marrow for transplantation by using dextran sedimentation [J].
Tsang, KS ;
Li, CK ;
Wong, AP ;
Leung, Y ;
Lau, TT ;
Li, K ;
Shing, MMK ;
Chik, KW ;
Yuen, PMP .
TRANSFUSION, 1999, 39 (11-12) :1212-1219
[93]  
TULLIEZ M, 1987, LEUKEMIA, V1, P44
[94]   ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab [J].
Tydén, G ;
Kumlien, G ;
Genberg, H ;
Sandberg, J ;
Lundgren, T ;
Fehrman, I .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (01) :145-148
[95]  
Ustun C, 1999, Ther Apher, V3, P275, DOI 10.1046/j.1526-0968.1999.00135.x
[96]   Pure red cell aplasia after allogeneic stem cell transplantation with reduced conditioning [J].
Veelken, H ;
Wäsch, R ;
Behringer, D ;
Bertz, H ;
Finke, J .
BONE MARROW TRANSPLANTATION, 2000, 26 (08) :911-915
[97]   Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion [J].
Verholen, F ;
Stalder, M ;
Helg, C ;
Chalandon, Y .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 73 (06) :441-446
[98]   EXPRESSION OF MAJOR BLOOD-GROUP ANTIGENS ON HUMAN ERYTHROID-CELLS IN A 2 PHASE LIQUID CULTURE SYSTEM [J].
WADA, H ;
SUDA, T ;
MIURA, Y ;
KAJII, E ;
IKEMOTO, S ;
YAWATA, Y .
BLOOD, 1990, 75 (02) :505-511
[99]   TRANSPLANTATION OF MAJOR ABO-INCOMPATIBLE BONE-MARROW DEPLETED OF RED-CELLS BY HYDROXYETHYL STARCH [J].
WARKENTIN, PI ;
HILDEN, JM ;
KERSEY, JH ;
RAMSAY, NKC ;
MCCULLOUGH, J .
VOX SANGUINIS, 1985, 48 (02) :89-104
[100]  
Webb I J, 1997, Biol Blood Marrow Transplant, V3, P267